VISWANATH NG, SHARMA M, BANDLAMUDI N, IDRIS I, SINGHAL R, MAHAWAR K and MADHOK B, 2023. Obes Surg. 33(1), 339-344
ALDAFAS R, CRABTREE T, VINORADOVA Y, GORDON JP and IDRIS I, 2023. Expert Rev Endocrinol Metab. 18(1), 95-110
LBBAN E, ASHOR A, SHANNON OM, IDRIS I and SIERVO M, 2023. Nutrition. 109, 111995
LOCH A, TAN KL, DANAEE M, IDRIS I and NG ML, 2023. 11(3), 944
KATASANI T, HOLT G, AL-KHYATT W and IDRIS I, 2023. Obes Surg. 33(7), 2016-2024
CRABTREE T, OGENDO JJ, VINOGRADOVA Y, GORDON J and IDRIS I, 2022. Expert Rev Endocrinol Metab. 17(3), 255-267
SAYDA MH, ABDUL AZIZ MH, GHARAHDAGHI N, WILKINSON DJ, GREENHAFF PL, PHILLIPS BE, SMITH K, IDRIS I and ATHERTON PJ, 2022. Scientific Reports.
MOZAFFAR B and IDRIS I, 2022. A literature review of Taste change and Zinc Deficiency after Bariatric Surgery: could there be a causal link? Obesity Surgery. (In Press.)
ABDULLA H, PHILLIPS B, WILKINSON D, GATES A, LIMB M, JANDOVA T, BASS J, LEWIS J, WILLIAMS J, SMITH K, IDRIS I and ATHERTON PJ, 2022. J Clin Endocrinol Metab. dgac613
GHARAHDAGHI N, RUDRAPPA S, BROOK MS, FARRASH W, IDRIS I, ABDUL AZIZ MH, KADI F, PAPAIONNOU K, PHILLIPS BE, SIAN T, HERROD PJ, WILKINSON DJ, SZEWCZYK NJ, SMITH K and ATHERTON PJ, 2022. J Cachexia Sarcopenia Muscle. 13(2), 1134-1150
SIMENACZ A, WILMINGTON R, GREEN C, ARDAVANI A and IDRIS I, 2022. The effectiveness of Liraglutide 3.0 (Saxenda) in bariatric patients within the Tier 3 and Tier 4 Services; a retrospective real-world clinical evaluation study Br J Diab. (In Press.)
RAMZAN I, ARDAVANI A, VANWEERT F, MELLETT A, ATHERTON P and IDRIS I, 2022. Nutrients. 14(20):4411(20), 4411
PATEL R, CRABTREE T, TAYLOR N, LANGELAND L, LANGELAND L, GAZIS T, MENDIS B, WILMOT EG and IDRIS I, 2022. Diabetic Medicine. 39(5), e14793
CRABTREE T, ADAMSON K, REID H, BARNES D, SIVAPPRIYAN S, BICKERTON A, GALLEN IW, FIELD B, IDRIS I and RYDER R, 2022. DOM. 24(7), 1398-1401
IDRIS I, ZHANG R, MAMZA JB, FORD M, MORRIS T, BANERJEE A and KHUNTI K, 2022. Diabetes Obes Metab. 24(11), 2138-2147
IDRIS I, 2022. The effectiveness of Liraglutide 3.0 (Saxenda) in bariatric patients within the Tier 3 and Tier 4 Services: a retrospective real-world clinical evaluation study Br J Diabetes.
SIMENACZ A, WILMINGTON R, GREEN C, ARDAVANI A and IDRIS I, 2022. Br J Diab. 22(2), 121-124
IDRIS I, ZHANG R, MAMZA JB, FORD M, MORRIS T, BANERJEE A, KHUNTI K, TULIP J and GREENER M, 2021. Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care Diabetes Obesity and Metabolism. (In Press.)
ALKHARAIJI M, ANYANWAGU U and IDRIS I, 2021. The metabolic and liver-related outcomes of bariatric surgery in adult patients with insulin-treated type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) at high risk of liver fibrosis Surgery for Obesity and Related Disease. 17(4), 792-798
WEBB J, MOUNT J, VON ARX L, RACHMAN J, SPANOPOULOS D, WOOD R, TRITTON T, MASSEY O and IDRIS I, 2021. Diabetes, Obesity and Metabolism.
ALKHARAIJI M, ANYANWAGU U, CRABTREE T, GORDON J and IDRIS I, 2021. Clin Obes. 11(6), e12486 (In Press.)
IDRIS I, ANNAMALAI N, AUNG T, BINNIAN I, GIBB FW, AFZAL MMI and RAMTOOLA S, 2021. Diabetic Medicine. e14684
IDRIS I, ZHANG R, MAMZA JB, FORD M, MORRIS T, BANERJEE A, KHUNTI K, TULIP J and GREENER M, 2021. Diabetes, Obesity and Metabolism. 23(10), 2207-2214
ARDAVANI A, AZIZ H, PHILLIPS BE, DOLEMAN B, RAMZAN I, MOZAFFAR B, ATHERTON PJ and IDRIS I, 2021. BMJ Open. 11(7), e044676
NEWMAN A, KEELEY V, PINNINGTON L, GREEN C, RICHES K, FRANKS PJ, IDRIS I and MOFFATT CJ, 2021. Lymphat Res Biol. 19(5), 431-441
ABDULLA H, BASS JJ, STOKES T, GORISSEN SHM, MCGLORY C, PHILLIPS BE, PHILLIPS SM, SMITH K, IDRIS I and ATHERTON PJ, 2019. Endocrinol Diabetes Metab. 2(4), e00085
DONNELLY, R., IDRIS, I. and FORRESTER, J. V., 2004. British Journal of Ophthalmology. VOL 88(PART 1), 145-151